[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591311":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":26,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Caffeine","ACTIVE_COMPARATOR","Participants will be administered a single dose of 200mg caffeine orally in study visite A, before exposing to a mild cold stimulus. Resting energy expenditure will be measured before an after administration of caffeine and cold exposure.",[13],"Drug: Caffeine (200 mg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo tablet orally in study visite B, before exposing to a mild cold stimulus. Resting energy expenditure will be measured before an after administration of placebo and cold exposure.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Caffeine (200 mg)","single dose of 200mg caffeine orally in study visit A",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"single dose of 1 tablet Placebo in study visit B",[15],[31],{"name":32,"affiliation":5,"role":33},"Matthias Betz, Prof.","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","0041 61 556 56 54","Matthias.Betz@usb.ch",{"name":40,"role":36,"phone":41,"phoneExt":26,"email":42},"Jaël Senn, MD","0041 61 328 70 79","jaelrut.senn@usb.ch",[44],{"facility":45,"status":46,"city":47,"state":26,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University Hospital Basel, Department of Endocrinology","RECRUITING","Basel","4031","Switzerland","CH",{"type":52,"coordinates":53},"Point",[54,55],7.57327,47.55839,{"lat":55,"lon":54},[58],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":59},"matthias.betz@usb.ch",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100591311","effect-of-caffeine-on-cold-stimulated-brown-adipose-tissue-activity-100591311",false,"NCT06978777","Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity","ACROBAT","Inclusion Criteria:\n\n* BMI 18.5 to 25 kg\u002Fm2\n* Able to give informed consent as documented by signature\n* Moderate caffeine consumption (1 to 3 cups of coffee per day)\n* Increase of EE in response to mild cold of ≥ 5% of REE\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to caffeine\n* Concomitant medication other than prescription free analgesics (paracetamol and NSAID) and oral contraceptives\n* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cardiac arrhythmia, hypertension, diabetes mellitus, hyper- or hypothyroidism)\n* History of depressive disorder or anxiety disorder\n* Smoker \u002F habitual tobacco use\n* Habitual excessive alcohol use\n* Regular consumption of caffeine containing energy drinks\n* Weight change of \\>5% within 3 months prior to inclusion\n* Systolic blood pressure \\>140 mmHg and\u002For diastolic blood pressure \\> 95 mmHg.\n* Resting heart rate \\>90 bpm\n* Hypersensitivity to cold (e.g. Raynaud syndrome)\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n* Enrolment into another study using ionizing radiation within the previous 12 months.\n* Pregnancy or lactation",true,"ALL","18 Years","40 Years",{"count":74,"type":75},12,"ESTIMATED","INTERVENTIONAL",[78],"NA","The purpose of the study is to asses brown adipose tissue activity after a cold mild stimulus, preceded by 200mg caffeine or placebo administration.",[81,82],"Brown Adipose Tissue (BAT) Physiology","Cold Exposure","2026-01-22",{"date":85,"type":86},"2026-01-23","ACTUAL",{"date":88,"type":86},"2026-01-21",{"date":90,"type":75},"2026-12-31",{"name":5,"class":6},1]